Key result
The optimal passage number of E38-ORF7 CPD PRRSV vaccine candidate is 20, as passages beyond this failed to induce effective immunity and accumulated mutations.
Why the study?
Porcine reproductive and respiratory syndrome virus causes major economic problems affecting swine health and productivity, prompting the evaluation of genetic stability and effective master seed passage threshold of an E38-ORF7 codon pair de-optimized vaccine candidate.
The optimal passage number for the E38-ORF7 CPD PRRSV vaccine candidate is 20, beyond which it loses genetic stability and immunogenicity.
Answers are grounded in this paper and cite their sources.
May inform CPD PRRSV vaccine development; leaves open optimal passage thresholds for field efficacy.
Porcine reproductive and respiratory syndrome virus (PRRSV) is major economic problem given its effects on swine health and productivity. Therefore, we evaluated the genetic stability of a codon pair de-optimized (CPD) PRRSV, E38-ORF7 CPD, as well as the master seed passage threshold that elicited an effective immune response in pigs against heterologous virus challenge. The genetic stability and immune response of every 10th passage (out of 40) of E38-ORF7 CPD was analyzed through whole genome sequencing and inoculation in 3-week-old pigs. E38-ORF7 CPD passages were limited to 20 based on the full-length mutation analysis and animal test results. After 20 passages, the virus could not induce antibodies to provide effective immunity and mutations accumulated in the gene, which differed from the CPD gene, presenting a reason for low infectivity. Conclusively, the optimal passage number of E38-ORF7 CPD is 20. As a vaccine, this may help overcome the highly diverse PRRSV infection with substantially enhanced genetic stability.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied Porcine reproductive and respiratory syndrome virus (PRRSV). E38-ORF7 CPD PRRSV passages was evaluated on Genetic stability and immune response against heterologous virus challenge. The optimal passage number of E38-ORF7 CPD PRRSV vaccine candidate is 20, as passages beyond this failed to induce effective immunity and accumulated mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: